Type 1 Diabetes Mellitus Clinical Trial
Official title:
A Randomized Control Trial in People With Type 1 Diabetes Mellitus Who Will Fast Ramadan: Does Insulin Timing and Dose Matter?
Fasting Ramadan is one of the five pillars of Islam and requested only from healthy adults to
abstain from eating and drinking from sunrise to sunset. People with type 1 diabetes mellitus
(TIDM) are exempted from fasting, as their chronic condition could be adversely affected by
fasting. Nevertheless, many insist on fasting and it has been experienced and advocated that
with proper education and follow-up with health care providers, people with uncomplicated
T1DM could safely fast Ramadan.
Adopted IDF-DAR guidelines for people with diabetes planning to fast Ramadan are available
but are based on opinions and largely untested. These current guidelines recommend a
significant reduction in insulin doses and a change of the timing of basal insulin and
highlight the increased risk of hypoglycemia. Our local DAFNE patient's experience with
fasting during the past years points towards no significant changes in insulin timing with
minor reductions of insulin without a significant increase in the risk of hypoglycemia. There
is no randomized control trial to test the efficacy of the IDF-DAR guidelines specifically
looking at changing basal insulin timing This study aims to assess whether insulin doses
require reduction and change of timing during Ramadan. We aim to compare the effectiveness
and safety of two management strategies. This will help to provide robust guidelines to help
both health care professionals and people with type 1 diabetes
INTRODUCTION/BACKGROUND
Diabetes and Ramadan (DAR) and IDF international collaboration created the IDF-DAR guidelines
which include the practical recommendations for HCP to better manage people with diabetes who
plan to fast Ramadan. The National Institute for Health and Clinical Excellence has
recommended implementation of structured education programs to help individuals enhance their
knowledge about diabetes and improve their management techniques. The educational program
needs to ensure that patients can cope with specific situations such as exercise, illness
which should extend to religious fasting.
We have developed and adopted a 5-day educational program widely used in the UK for delivery
in Kuwait. The course trains adults with Type 1 Diabetes in the UK to manage their condition
more effectively using multiple injections. As part of our course, DAFNE graduates receive
yearly Ramadan diabetes educational specific session (separate from the main 5-day course)
and all DAFNE graduates are invited. During the 6 hours session, we seek patients' views,
willingness to fast and introduced to the specific food that commonly consumed during
Ramadan. Previous personal experiences of fasting and problems encountered are collected.
Patients who are intending to fast and whom we deem safe to undertake this, receive clear and
practical guidance on safe fasting during Ramadan.
Current Gaps in the Literature
Most intervention studies up to date have been performed in controlled conditions, using a
small number of participants and with a short duration of intervention, ie not closely
related to real-life. The variability of insulin regimens, dietary patterns and physical
activity levels and the complexity of ways in which they are tested make it difficult to
identify the individual effects of each component on diabetes outcomes. As a result, further
research is needed to help expand the currently available knowledge regarding the management
of diabetes and its associated complications when fasting during Ramadan. We believe that
large, randomized, controlled intervention trials are necessary to broaden our understanding
of the implications of fasting and evaluate guidance without bias. Further research into the
effect of fasting during Ramadan on both high (measured by SMBG and HbA1C) and low glucose
(measured by the incidence of hypoglycemia) is required. Robust evaluation of evidence-based
guidelines will lead to useful practical assistance for patients who can fulfill religious
obligations despite the additional burden of insulin-treated diabetes. This pilot study
builds on an educational program, DAFNE which includes many of the elements of flexible
eating and insulin dose adjustment which should permit patients to fast safely.
Study Rationale
Adopted IDF-DAR guidelines are available but recommend a significant reduction in insulin
doses and change to the timing of basal insulin for MDI users. There is no evidence that
fasting increases the risk of hypoglycemia, and glucose tends to be higher during Ramadan, as
a result of a reduction in insulin doses.
Local DAFNE patient's experience with fasting during the past years points towards no
significant changes in insulin doses (minor reductions were needed in basal or bolus insulin
doses) without the need of the change of basal insulin timing, however we are not aware
without running a randomized control trial (RCT) to test DAFNE guidelines versus DAR-IDF
guidelines.
OBJECTIVES / HYPOTHESIS
The primary objectives of this study are to assess whether insulin doses require reduction
during Ramadan and change of timing and whether fasting increases the risk of hypoglycemia
for people with T1DM who fast Ramadan.
Hypothesis:
This study hypothesized no changes in insulin dose timing and fasting does not increase the
risk of hypoglycemia.
METHODOLOGY
Potential patients will be identified via DAFNE database at DDI. Candidate subjects who are
current users of (FSL) and administer insulin via (MDI) will be contacted by phone and will
be offered conditional participation in the study. Those agreeable will be given the consent
form with the preferred language (Arabic or English) and will be scheduled a study visit. The
same will be done for insulin pump users.
Study design
Open-label randomized controlled trial in people with uncomplicated T1DM fasting during
Ramadan (1 month) comparing insulin management according to IDF-DAR guidelines (IDF-DAR arm)
and local experience (DAFNE arm), on time spent in range (TIR) of 4-10 mmol/L, and
hypoglycaemic self-reported episodes.
Primary outcome:
1. Percentage TIR 4-10mmol/L
2. Rate of self-reported hypoglycemia by participants
Secondary outcomes:
1. Percentage time <4mmol/L
2. Percentage time >10mmol/L
3. Number of sensors detected hypoglycaemic events
4. Number of days needed to break the fast
Inclusion/exclusion criteria:
Mentioned in separate section
Intervention:
The intervention in this study is insulin dosing and timing during Ramadan, and it will be
assessed by creating two groups of participants that are similar to one another in all
respects, except to the intervention to be assessed. Participants will be DAFNE graduates who
were trained properly on carbohydrate counting and adjusting insulin doses according to the
carbs consumed. The whole cohort will be using the same insulin regimen; multiple daily
injections (MDI) and monitoring glucose using the same monitoring systems; flash glucose
monitoring (FGM) system: FreeStlye Libre (FSL) Reader and sensors, and self-monitoring of
blood glucose (SMBG) using the FreeStyle optimum test strips, or insulin pump.
The null hypothesis is that there is no difference in the rates of hypoglycemia between basal
insulin taken at iftar time versus bedtime in people with T1DM during fasting Ramadan.
Ramadan Workshop
DAFNE structured education program was conducted to all subjects in a stage their life with
T1DM. Consequently, subjects are familiar with carbohydrate counting and aware of dose
adjustments needed to cover their meals. Nevertheless, this workshop will include food tables
with real food models of traditional Ramadan plates. The workshop includes advices on healthy
eating habits during Ramadan. General instructions will be provided to all participants which
are part of DAFNE Ramadan protocol.
Ramadan Visits, Daily messages, and Calls
Visits: Weekly or whenever required, to upload FSL reader and adjust doses without crossing
the arm recommendations for adjustments. This can be done in person or via the cloud Daily
Messages: Did you fast full day? If no, was it due to hypoglycemia, and did you check BG to
confirm hypoglycemia? Daily count of hypoglycemic episodes? Was all confirmed with SMBG? Are
you wearing a glucose sensor, and scanning readings at least once every 8 hours? Calls: If
participant was not answering messages, calls will be initiated. A message or call should be
performed in the last day of Ramadan to instruct participants about the insulin dosing and
timing post-Ramadan
Post-Ramadan Visit:
1. Upload FSL reader
2. Physical examination will be repeated, including weight and routine blood will be
collected again including HbA1C, FBC, U&Es with eGFR, full chemistry, urine ACR within
three months
3. This will conclude the study visits for the subject
DATA ANALYSIS
For statistical analysis, this can be done using two-tailed unpaired t-test as we are
comparing results of different subjects who are in different conditions and the change can be
rise or fall in time in range.
Telemonitoring data including daily questionnaires, WhatsApp messages, food logs, and meal
pictures will be collected and added to an excel sheet for analysis.
FreeStlye libre software will be used to extract reports and data export readings of FSL
readers. The following analysis will be carried out for both arms and for all fasted days:
1. Total average of 24 hours of glucose
2. Estimated A1c
3. Percentage time in range 4.0-10mmol/L
4. Percentage time spent <4.0mmol/L
5. Percentage of time spent >10mmol/L
6. Low glucose events
7. Low glucose duration
8. Total patient-reported hypoglycemia events (from telemonitoring data mentioned above)
One-way ANOVA to compare means of percentage time in all above glucose ranges with an
alpha <0.05
IMPORTANCE OF THE RESEARCH OUTCOMES
IDF-DAR guidelines recommend reducing insulin doses in people with T1DM or insulin-dependent
T2DM to prevent hypoglycemia especially in the 3 to 4 hours before iftar, in addition to
changing the basal insulin timing. DAFNE earlier work at DDI demonstrated that fasting
Ramadan did not require a significant reduction of background basal insulin (most 5-10% if
needed) without reduction of meal bolus insulin. It also advocates that there is no increased
risk of hypoglycemia in Ramadan if done with the support of diabetes with prior education and
close glucose monitoring. However, there is significant evidence that glucose tends to be
higher during Ramadan especially post-iftar, as a result of eating feasting behavior and most
probably a reduction in insulin doses as per guidelines. There is no consensus between
guidelines and local experience and no evidence about the cut-off reduction in insulin doses
which requires running this randomized control trial which hypothesized that the change in
eating behavior in Ramadan does not change insulin requirement and carb counting will provide
safe insulin dosing during Ramadan similar to that outside Ramadan
ETHICAL CONSIDERATIONS Informed Consent Forms
We will give a patient information sheet for the participant to keep and ask for written
informed consent. We will document that 3 copies have been distributed: one to the
participant, another to his/her doctor and one for the study team
CONFIDENTIALITY
All hard copies of any study material will be kept in locked cabinets on the premises of DDI.
Subject identifiable information will be only available to study team and ethics committee
for inspection in case this becomes required.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04476472 -
Omnipod Horizon™ Automated Glucose Control System Preschool Cohort
|
N/A | |
Completed |
NCT03635437 -
Evaluation of Safety and Diabetes Status Upon Oral Treatment With GABA in Patients With Longstanding Type-1 Diabetes
|
Phase 1/Phase 2 | |
Completed |
NCT04909580 -
Decision Coaching for Youth and Parents Considering Insulin Delivery Methods for Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT00679042 -
Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol
|
Phase 3 | |
Completed |
NCT03293082 -
Preschool CGM Use and Glucose Variability in Type 1 Diabetes
|
N/A | |
Completed |
NCT04016662 -
Automated Insulin Delivery in Elderly With Type 1 Diabetes (AIDE T1D)
|
Phase 4 | |
Completed |
NCT02527265 -
Afrezza Safety and Pharmacokinetics Study in Pediatric Patients
|
Phase 2 | |
Completed |
NCT03738865 -
G-Pen Compared to Glucagen Hypokit for Severe Hypoglycemia Rescue in Adults With Type 1 Diabetes
|
Phase 3 | |
Completed |
NCT03240432 -
Wireless Innovation for Seniors With Diabetes Mellitus
|
N/A | |
Completed |
NCT03168867 -
Effectiveness Trial of an E-Health Intervention To Support Diabetes Care in Minority Youth (3Ms)
|
N/A | |
Completed |
NCT03674281 -
The VRIF Trial: Hypoglycemia Reduction With Automated-Insulin Delivery System
|
N/A | |
Completed |
NCT03669770 -
Ultrasound Classification and Grading of Lipohypertrophy and Its Impact on Glucose Variability in Type 1 Diabetes
|
||
Recruiting |
NCT03682640 -
Azithromycin Insulin Diet Intervention Trial in Type 1 Diabetes
|
Phase 2 | |
Recruiting |
NCT04096794 -
Chinese Alliance for Type 1 Diabetes Multi-center Collaborative Research
|
||
Completed |
NCT02882737 -
The Impact of Subcutaneous Glucagon Before, During and After Exercise a Study in Patients With Type 1 Diabetes Mellitus
|
N/A | |
Recruiting |
NCT02745808 -
Injectable Collagen Scaffold™ Combined With HUC-MSCs for the Improvement of Erectile Function in Men With Diabetes
|
Phase 1 | |
Completed |
NCT02562313 -
A Trial Investigating the Continuous Subcutaneous Insulin Infusion of a Liquid Formulation of BioChaperone Insulin Lispro in Comparison to Humalog®
|
Phase 1 | |
Completed |
NCT02558491 -
Feasibility of a Decision Support System to Reduce Glucose Variability in Subject With T1DM
|
N/A | |
Withdrawn |
NCT02579148 -
Collagen Scaffolds Loaded With HUCMSCs for the Improvement of Erectile Function in Men With Diabetes
|
Phase 1 | |
Withdrawn |
NCT02518022 -
How to be Safe With Alcoholic Drinks in Diabetes
|
N/A |